CA-PLUS
9.5.2022 14:02:08 CEST | Business Wire | Press release
Plus, a global provider of self-driving truck technology, announced today that it has selected Velociti, a global leader in fleet technology solutions, as the deployment and maintenance partner for the national Plus Build program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510005059/en/
The Plus Build program takes less than a day to turn new and existing Class 8 freight trucks into semi-autonomous trucks by equipping them with state-of-the-art lidar, radar, and camera sensors and Plus’s proprietary autonomous driving software. The result is PlusDrive, the industry’s first commercially available autonomous trucking solution. PlusDrive improves safety, enhances driver comfort, and saves at least 10% in fuel costs. Installation is performed at locations most convenient to customers, in or near major transportation hubs across the U.S. Maintenance services are available nationwide by utilizing mobile resources to meet customers where they are.
Shawn Kerrigan, COO and Co-founder of Plus, said: “Plus Build helps companies unlock the benefits of autonomous driving technology today by quickly modernizing trucks to improve their safety and uptime. Velociti’s unmatched technology installation and service network will help us get PlusDrive into the hands of more truck drivers across the country to make their jobs safer, easier, and better.”
Through the Plus Build program and partnership with Velociti, Plus is now deploying PlusDrive nationwide. Some of the world’s largest fleets and truck manufacturers are already participating in Plus Build and are operating PlusDrive-enabled trucks on the road today. In addition to Velociti’s technology installation services, Plus is implementing Velociti’s VeloCare solution, a flagship proactive system-health monitoring program including remote and mobile services to maximize technology uptime.
“Partnering with Plus to provide our services as an important part of the PlusDrive solution leverages Velociti’s decades of experience deploying and maintaining innovative fleet technologies. We are excited to enter into this strategic partnership to help PlusDrive customers realize the benefits this transformational technology brings to their businesses and to the transportation industry,” said Ryan Powell, Senior Vice President at Velociti.
Supervised by a truck operator, PlusDrive can autonomously handle the following in normal traffic conditions on a highway:
- Lane centering
- Driver initiated lane change
- Traffic jam assist
- Predictive fuel optimization
- Adaptive cruise control (down to zero)
- Lane merging
- Driver attentiveness detection
- Operational Design Domain (ODD) checker
- Self-calibration
- Over-the-air updates
For more information on the Plus Build program or PlusDrive, please contact sales@plus.ai .
About Plus
Plus is a global leader in the autonomous trucking revolution, with award-winning high-performance full-stack driverless technology. Named by Fast Company as one of the World’s Most Innovative Companies of 2022, Plus is the only autonomous driving company with customers operating its product on the road today. Working with one of the largest companies in the U.S., vehicle manufacturers and others, Plus is making long-haul trucking safer, more fuel efficient, more sustainable, and more comfortable for the drivers. Plus has received a number of industry awards and distinctions for its transformative technology and business momentum from Fast Company , Insider , Consumer Electronics Show , AUVSI , and others.
For more information, please visit www.plus.ai or follow us on LinkedIn or YouTube .
About Velociti
Velociti, a global provider of enterprise technology solutions for more than 25 years, helps meet complex business needs by optimizing technology investments, lowering costs, and improving employee and customer experience. Its innovative design, rapid installation and deployment, and proactive support services for a broad range of transportation and networking technologies are provided by a highly experienced team of engineers, project managers, certified technicians and customer success representatives. Velociti serves enterprises in transportation and logistics, construction, retail, food service, manufacturing, distribution, government, and hospitality including many Fortune 500 companies.
For more information visit http://www.velociti.com or call toll free (855)-233-7210.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom